Evidence map›Paper›PMID 41582686›Full record

ArticleDisease models & mechanisms2026

MicroRNA-21 promotes dysregulated lipid metabolism and hepatocellular carcinoma.

Chad VanSant-Webb, Jessye C Castro, Audrey Y Su, Kiandra Hawkins, Aavrati Saxena, Jillian Wright, Richard Smith, Marco Fragoso-García, Yian Ann Chen, Carrie Barton and 4 more

Abstract read
In one paragraph

Article in Disease models & mechanisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Chad VanSant-WebbDepartment of Pathology, University of Utah, 15 North Medical Drive East, Salt Lake City, UT 84101, USA.
Jessye C CastroDepartment of Pathology, University of Utah, 15 North Medical Drive East, Salt Lake City, UT 84101, USA.
Audrey Y SuDepartment of Pathology, University of Utah, 15 North Medical Drive East, Salt Lake City, UT 84101, USA.
Kiandra HawkinsDepartment of Pathology, University of Utah, 15 North Medical Drive East, Salt Lake City, UT 84101, USA.
Aavrati SaxenaDepartment of Pathology, University of Utah, 15 North Medical Drive East, Salt Lake City, UT 84101, USA.
Jillian WrightHuntsman Cancer Institute, 2000 Circle of Hope Way, Salt Lake City, UT 84101, USA.
Richard SmithDepartment of Pathology, University of Utah, 15 North Medical Drive East, Salt Lake City, UT 84101, USA.
Marco Fragoso-GarcíaDepartment of Pathology, Albert Einstein College of Medicine, 1301 Morris Park Avenue, Bronx, NY 10461, USA.
Yian Ann ChenDepartment of Population Health Sciences, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA.
Carrie BartonOffice of Comparative Medicine, 50 S 2030 E, Salt Lake City, UT 84132, USA.
Chris StubbenHuntsman Cancer Institute, 2000 Circle of Hope Way, Salt Lake City, UT 84101, USA.
Ryan M O'ConnellDepartment of Pathology, University of Utah, 15 North Medical Drive East, Salt Lake City, UT 84101, USA.
Gregory S DuckerHuntsman Cancer Institute, 2000 Circle of Hope Way, Salt Lake City, UT 84101, USA.ORCID 0000-0002-8651-6846
Kimberley J EvasonDepartment of Pathology, University of Utah, 15 North Medical Drive East, Salt Lake City, UT 84101, USA.ORCID 0000-0002-0471-2473

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Serotonergic antidepressants as liver tumor preventivesR01CA222570 · NCI · UNIVERSITY OF UTAH · PI EVASON, KIMBERLEY JANE · 2018 to 2022
$1.8M
Huntsman Cancer Institute (HCI) Cancer Genetics, Epigenetics, Models, and Signaling (Cancer GEMS) Training ProgramT32CA265782 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Donald E Ayer, Sheri L Holmen · 2023 to 2026
$1.0M
American Cancer Society DBG-23-1037804-01-TBEAmerican Cancer Society RSG-22-014-01-CCBDamon Runyon Cancer Research Foundation DR 61-20Huntsman Cancer FoundationHuntsman Cancer Institute, University of UtahNCI NIH HHS P30CA042014NCI NIH HHS R01CA222570-NIH-NCINCI NIH HHS T32 CA265782NIH HHS R01CA222570University of Utah
6 · The paper itself

Abstract

The prevalence of hepatocellular carcinoma (HCC) is rising in parallel with increasing obesity and metabolic dysfunction-associated steatohepatitis (MASH). MicroRNAs (miRNAs) are key post-transcriptional regulators of gene expression and attractive targets for HCC therapy. Here, we sought to identify and characterize dysregulated miRNAs in MASH-driven HCC (MASH-HCC). We profiled miRNA expression in liver tissue from patients with MASH or MASH-HCC and in zebrafish HCC driven by activated β-catenin (CTNNB1), one of the most commonly mutated oncogenes in MASH-HCC. We found overlap between dysregulated human and zebrafish miRNAs, including microRNA-21 (miR-21), which was increasingly upregulated from normal liver to MASH to MASH-HCC. We generated transgenic zebrafish that overexpress or sponge miR-21 in hepatocytes. We found that miR-21 overexpression caused larval liver overgrowth and increased HCC, while miR-21 sponge suppressed β-catenin-driven larval liver overgrowth. By performing histological and lipidomics analysis, we found that overexpression of miR-21, like activated β-catenin (ABC), suppressed lipid accumulation in response to a high cholesterol diet and increased accumulation of acylcarnitines. Thus, miR-21, which is similarly upregulated in human and zebrafish HCC, promotes lipid metabolic changes that may help drive hepatocarcinogenesis.

Indexed as

Carcinoma, HepatocellularLipid MetabolismLiver NeoplasmsMicroRNAsAnimalsAnimals, Genetically Modifiedbeta CateninCarnitineFatty LiverGene Expression Regulation, NeoplasticHepatocytesHumansLarvaLiverUp-RegulationZebrafishacylcarnitinebeta CateninCarnitineMicroRNAsMIRN21 microRNA, humanAcylcarnitinesLiverSteatosisZebrafishβ-catenin

Identifiers

PMID41582686
PMCPMC12994464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.